Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Molecular Biosystems

This article was originally published in The Gray Sheet

Executive Summary

Will pay $3 mil. in cash and $1.5 mil. in MBI common stock to a class of stock purchasers under a lawsuit settlement given preliminary approval by the U.S. District Court for the Southern District of California, the company reports. The suit, filed in November 1992, "claimed that the company, its directors, and certain of its officers misled investors as to the timing of and prospects for approval" of the company's Albunex echocardiography contrast agent, MBI notes. The company "denied all claims of wrongdoing and maintains this denial as part of the settlement agreement." The insurer for directors and officers will provide $800,000 of the settlement's cash payment. As a result of the pact, MBI will record a $3.7 mil. charge to earnings for its fourth fiscal quarter ended March 31
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT002181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel